Spirobrorphine
Appearance
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C21H24BrN3O |
| Molar mass | 414.347 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Spirobrorphine is a synthetic opioid chemical compound which has been sold as a designer drug, first reported in the USA in February 2026.[1] It was added to the controlled drug schedules in Canada in June 2026.[2] Its pharmacology has not yet been studied but it is believed to be a potent opioid narcotic in a similar manner to related compounds such as spirochlorphine and R6372.
See also
[edit]References
[edit]- ↑ "Emerging Global Synthetic Opioid Threats: Benzimidazol-2-ones – The Orphines. Colombo Plan Health Alert, February 2026" (PDF). www.cfsre.org.
- ↑ "Order Amending Schedule V to the Controlled Drugs and Substances Act (R 29676, Spirobrorphine and Spirochlorphine): SOR/2026-71. Canada Gazette, Part II, Volume 160, Number 9. 17 April 2026". gazette.gc.ca. Government of Canada, Public Works and Government Services Canada, Integrated Services Branch, Canada Gazette.